Bevacizumab and everolimus in renal cancer: A rational way forward

Journal of Clinical Oncology

Volumn 28, Issue 33, 2010, Pages

  Stadler, Walter M ^a   Phillips, George ^b   George, Daniel J ^a   Halabi, Susan ^c   Small, Eric ^d  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF VERMONT   (United States)

^c DUKE UNIVERSITY   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN; VASCULOTROPIN RECEPTOR;

DRUG EFFICACY; DRUG TARGETING; HUMAN; KIDNEY CANCER; LETTER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, RENAL CELL; HUMANS; KIDNEY NEOPLASMS; SIROLIMUS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 79951909839     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.30.7934     Document Type: Letter

References (4)

1. Escudier B: How to interpret phase II data for everolimus plus bevacizumab in renal cell carcinoma. J Clin Oncol 28:2125-2126, 2010
2. Hainsworth JD, Spigel DR, Burris HA III, et al: Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma. J Clin Oncol 28:2131-2136, 2010
3. Escudier B, Koralewski P, Pluzanska A, et al: A randomized, controlled, double-blind phase III study (AVOREN) of bevacizumab/interferon-α2a vs placebo/interferon-α2a as first-line therapy in metastatic renal cell carcinoma. J Clin Oncol 25:18s, 2007 (abstr 3)
4. Rini BI, Halabi S, Rosenberg JE, et al: Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 26:5422-5428, 2008